LOG IN
Analysis
Featured Analysis
Articles by Category
Current Editions
Data Graphics
Discovery & Translation
Hot Topics
BioCentury Podcasts
Special Reports & Presentations
White Papers
BCIQ Data
BCIQ
Company Profiles
Product Profiles
Target Profiles
Financial Dashboards
Events
All Events
East-West Healthcare Reception
Bio€quity Europe
Grand Rounds — U.S.
Grand Rounds — Europe
China Healthcare Summit
East-West Biopharma Summit 2026
Bio€quity Europe 2026
The BioCentury Show
Podcast: BioCentury This Week
Webinars
My Workspace
About BioCentury
Management
Analysts & Research Team
Scientific Advisory Board
Contact
Contact Us
Forgot Password
Request a Subscription
Sponsorship & Branding Inquiry
Media Kit
Request BioCentury's BCIQ Brochure
Customer Resource Center
Career Opportunities
Request a Trial
Company Profiles
Target Profiles
Product Profiles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Company Profiles
Target Profiles
Product Profiles
China Healthcare Summit
Bio€quity Europe
Explore BCIQ profiles by entering a company name.
REQUEST A FREE TRIAL
Overview
Pipeline
Deals
Financings
Earnings Summary
Stock Summary
Articles
Kineta Inc.
Headquarters:
Seattle, WA, United States of America
Website:
http://www.kinetabio.com
Year Founded:
2008
Status:
Public
Industry Sector:
HealthTechnology
CEO:
Shawn P. Iadonato, PhD
Number Of Employees:
5
Enterprise Value:
$4,391,815
PE Ratio:
-0.21
Exchange/Ticker 1:
NASDAQ:KA
Exchange/Ticker 2:
N/A
Latest Market Cap:
$3,765,500
BioCentury
|
Jul 28, 2023
Deals
Biotech reverse mergers growing amid improving market conditions
Are 2023’s reverse mergers another sign of an improving biotech environment?
Read More
BioCentury
|
Jul 18, 2023
Management Tracks
Gosebruch named CEO of Neumora
Plus: Petti becomes CEO at Leucid Bio, and updates from Acelyrin, Larimar, Pharming and more
Read More
BioCentury
|
Jun 6, 2022
Deals
Sale of programs to J&J leaves Yumanity as shell for Kineta reverse merger
Combined company to advance Seattle biotech’s cancer programs as Yumanity’s eight-year history in neurodegeneration comes to a close
Read More
BioCentury
|
May 7, 2020
Finance
May 6 Quick Takes: Grail raises year’s largest venture round; plus fresh funds for Insmed, Kura, TG, BerGenBio, Limbix and Kineta
Read More
BioCentury
|
Feb 14, 2020
Targets & Mechanisms
Entrepreneur watch: Iwasaki targets the lymphatic system to clear brain tumors
After starting two companies this year, Yale’s Akiko Iwasaki clears glioblastoma in mice via brain lymphatics
Read More
BioCentury
|
Sep 27, 2017
Distillery Therapeutics
Infectious disease
Read More
BioCentury
|
Sep 8, 2017
Company News
Merck acquires cancer play Rigontec
Read More
BioCentury
|
Sep 6, 2017
Company News
Merck acquires cancer play Rigontec
Read More
BioCentury
|
Sep 6, 2017
Preclinical News
Human mAbs could treat Lassa fever
Read More
BioCentury
|
May 31, 2017
Distillery Therapeutics
Transplant
Read More
Items per page:
10
1 - 10 of 30